UK Renal Registry, Bristol, UK.
Nephron Clin Pract. 2012;120 Suppl 1:c145-74. doi: 10.1159/000342851. Epub 2012 Sep 1.
The UK Renal Association (RA) and National Institute for Health and Clinical Excellence (NICE) have published clinical practice guidelines which include recommendations for management of anaemia in established renal failure.
To determine the extent to which the guidelines for anaemia management are met in the UK.
Quarterly data were obtained regarding haemoglobin (Hb) and factors that influence Hb from renal centres in England, Wales, Northern Ireland (EWNI) and the Scottish Renal Registry for the incident and prevalent renal replacement therapy (RRT) cohorts for 2010.
In the UK, in 2010 53.6% of patients commenced dialysis therapy with Hb ≥ 10.0 g/dl (median Hb 10.1 g/dl). The median Hb of haemodialysis (HD) patients was 11.5 g/dl with an interquartile range (IQR) of 10.5-12.3 g/dl. Of HD patients 84.6% had Hb ≥ 10.0 g/dl. The median Hb of peritoneal dialysis (PD) patients in the UK was 11.6 g/dl (IQR 10.6-12.5 g/dl). Of UK PD patients, 87.2% had Hb ≥ 10.0 g/dl. The median ferritin in HD patients in EWNI was 444 µg/L (IQR 299-635) and 96% of HD patients had a ferritin ≥ 100 µg/L. The median ferritin in PD patients was 264 µg/L (IQR 148-426) with 86% of PD patients having a ferritin ≥ 100 µg/L. In EWNI the mean Erythropoietin Stimulating Agent (ESA) dose was higher for HD than PD patients (9,020 vs. 6,202 IU/week).
Of prevalent HD patients, 52.7% had Hb ≥ 10 and ≤ 12 g/dl. Of prevalent PD patients, 54.3% had Hb 10.5-12.5 g/dl.
英国肾脏协会（RA）和国家卫生与临床优化研究所（NICE）发布了临床实践指南，其中包括对已确诊肾衰竭患者贫血管理的建议。
确定英国在贫血管理指南方面的实施情况。
2010 年，从英格兰、威尔士、北爱尔兰（EWNI）和苏格兰肾脏登记处的肾脏中心定期获得有关血红蛋白（Hb）和影响 Hb 的因素的数据，用于分析新开始接受肾脏替代治疗（RRT）和持续性 RRT 的患者队列。
2010 年，英国有 53.6%的患者开始透析治疗时 Hb≥10.0g/dl（中位数 Hb 为 10.1g/dl）。血液透析（HD）患者的中位数 Hb 为 11.5g/dl，四分位距（IQR）为 10.5-12.3g/dl。84.6%的 HD 患者 Hb≥10.0g/dl。英国腹膜透析（PD）患者的中位数 Hb 为 11.6g/dl（IQR 10.6-12.5g/dl）。87.2%的 UK PD 患者 Hb≥10.0g/dl。EWNI 中 HD 患者的中位数铁蛋白为 444μg/L（IQR 299-635），96%的 HD 患者铁蛋白≥100μg/L。PD 患者的中位数铁蛋白为 264μg/L（IQR 148-426），86%的 PD 患者铁蛋白≥100μg/L。在 EWNI，HD 患者的平均红细胞生成素刺激剂（ESA）剂量高于 PD 患者（9020 vs. 6202IU/周）。
在现有的 HD 患者中，52.7%的患者 Hb≥10 且≤12g/dl。在现有的 PD 患者中，54.3%的患者 Hb 为 10.5-12.5g/dl。
